The second round of competitions is now on with the entry of Galvusmet generics.

If the first round was held between generics before and after Galvusmet’s substance patent expiry, the second round this time expected this time is set to start with the release of Galvusmet generics that come in all dosage forms.

According to the industry on the 26th, Daewoong Bio, Mothers Pharmaceutical, and Korea Hutex Pharmaceutical, led by the contracted CDMO Genuone Science, will launch all dosage forms of Galvusmet generics.

Galvusmet is a combination of the DPP-4 inhibitor vildagliptin and metformin hydrochloride. Novartis Korea received approval for the drugs in 2008 in Korea